PHASE II STUDY OF ERLOTINIB AS A FIRST-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER PATIENTS ACCORDING TO THEIR CLINICAL PREDICTORS

被引：0
|
作者：
Lee, D. H. [1 ]
Kim, H. T. [2 ]
Kim, S. [1 ]
Suh, C. [1 ]
Lee, J. [1 ]
机构：
[1] Asan Med Ctr, Dept Internal Med, Div Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Ctr Lung Canc, Goyang, South Korea
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] First-line immunotherapy in advanced non-small-cell lung cancer
    Noronha, Vanita
    Mehta, Prashant
    Malik, Prabhat Singh
    Patel, Amol
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
  • [42] Is erlotinib for first-line use in EGFR plus non-small-cell lung cancer cost-effective?
    Veenstra, David L.
    Bajaj, Preeti S.
    Carlson, Josh John
    Goertz, Hans-Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study
    Tartarone, A
    Romano, G
    Iodice, G
    Capobianco, A
    Coccaro, M
    Bochicchio, A
    Di Leo, P
    Ardito, R
    Di Renzo, N
    TUMORI, 2005, 91 (02) : 131 - 134
  • [44] A PHASE II STUDY OF FIRST-LINE BORTEZOMIB (B) IN PATIENTS (PTS) WITH STAGE IIIB/IV NON-SMALL-CELL LUNG CANCER (NSCLC)
    Planchard, D.
    Besse, B.
    Meric, J. B.
    Veillard, A. S.
    Pignon, J. P.
    Chan, K.
    Mathiot, C.
    Lumbroso, J.
    Lafontaine, C.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 96 - 96
  • [45] A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations
    Wang, Pingli
    Cao, Liming
    Tian, Panwen
    Ren, Shengxiang
    Miao, Liyun
    Zhou, Chengzhi
    Fan, Yun
    Li, Yuping
    Lv, Dongqing
    Zhao, Xin
    Yang, Mei
    Zhu, Chaonan
    Yu, Bing
    Xu, June
    Song, Yong
    Wang, Kai
    CANCER COMMUNICATIONS, 2023, 43 (09) : 1059 - 1063
  • [46] Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
    Rusthoven, JJ
    Eisenhauer, E
    Butts, C
    Gregg, R
    Dancey, J
    Fisher, B
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1194 - 1199
  • [47] Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
    Brahmer, J. R.
    Lee, J. W.
    Traynor, A. M.
    Hidalgo, M. M.
    Kolesar, J. M.
    Siegfried, J. M.
    Guaglianone, P. P.
    Patel, J. D.
    Keppen, M. D.
    Schiller, J. H.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 302 - 308
  • [48] Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
    Chu, T.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Shi, C.
    Zhang, X.
    Qian, J.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S589 - S590
  • [49] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
    Xu, Bei
    Liu, Peng
    Yin, Yongmei
    Liu, Ping
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
  • [50] Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Hensing, Thomas A.
    Rademaker, Alfred
    Hart, Eric M.
    Blum, Matthew G.
    Milton, Daniel T.
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3284 - 3289
12345